Old News Folks
Andy Biotech @AndyBiotech 5h5 hours ago @adamfeursein
$EXEL $BMY No question that nivo will be used before cabo, safety profile is the key (esp Gr3/4 SAEs)
Google it, this is correct and thanks !!
Sentiment: Strong Buy
absolutely 24 million have schzo- billions to be made
Big Money in Eye Drugs For Big Pharmas.
The One Killer Feature Apple TV Needs Isn't Ready Yet
By: Robert Hof
The rights issues and a reluctance by programmers and networks to endanger their cash cows have stalled that service. Original programming is the only solution to Apple’s biggest problem in the video world–that is, that nobody wants to sell Apple content rights.
Virtual devices $15,000 each
MFI - Money Flow Index
Large Outflow of Money Witnessed in Kite Pharma, Inc.
Sunday August 23, 2015 by Lauren Austin in Market Indices · 0
By : Ryan Barnes
Zynerba transdermal delivery tech has 10 patents in the United States, and more than 30 abroad. Zynerba is the only company with IP in the area of transdermal cannabis therapeutics. The total “end market potential” for the indications Zynerba could treat amounts to over $7 billion, so there is plenty of runway for success. GW Pharmaceuticals (NASDAQ: GWPH) was about the same size company as Zynerba, and traded for about $9 a share. Now they trade for over $110 and GWPH is a $2 billion plus company. If Zynerba shows itself to be on a similar flight path to GWPH, expect to see some serious M&A buyers lining up to make a bid for Zynerba